Avisa Diagnostics Inc.

Avisa Diagnostics Inc. is a clinical-stage medical device company focused on advancing rapid, point-of-care diagnostic solutions in the healthcare sector. Its core innovation is the Avisa BreathTest, a novel drug/device biomarker platform designed for ultra-rapid detection and monitoring of virulent bacterial pathogens, particularly in pulmonary infections. The test enables healthcare professionals to assess bacterial load in patients' lungs within minutes by having the patient inhale or ingest a proprietary drug substrate, streamlining the diagnosis of conditions such as bacterial pneumonia, cystic fibrosis, tuberculosis, and community-acquired and ventilator-associated pneumonia. By leveraging a quantitative breath test that delivers results in approximately ten minutes, Avisa Diagnostics addresses a significant need for timely and accurate diagnosis in respiratory care. The company’s ongoing clinical development and planned pivotal trials highlight its role in advancing innovative diagnostic methods with potential for widespread impact in infectious disease management and respiratory healthcare research.